Treatment with the TLR7 agonist imiquimod promotes the infiltration of CD4+ and CD8+ T cells, decreases the absolute number of Tregs in the tumor microenvironment and establishes anti-tumor immune memory in mice [60, 61]. Here, TLR7 is linked to neoplasm.